Cited by 148PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 108 of the 110 references it cites were found in a registry or an index.

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Open access

Klempner, Samuel J., Myers, Andrea P., Cantley, Lewis C.·2013·Cancer Discovery

DOI 10.1158/2159-8290.cd-13-0063PMC PMC3864542

Open this paper in CoChat — free account

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is one of the most frequently mutated pathways in cancer, and is actively being pursued as a therapeutic target. Despite the importance of the PI3K pathway in cancer, durable responses to PI3K pathway-targeted therapies are uncommon with monotherapy. Several in vitro and xenograft models have elucidated compensatory signaling and genomic changes which may limit the therapeutic effectiveness of PI3K inhibitors in the clinic. Future clinical trials with prospective evaluation of tumor signaling and genomic changes are likely to identify novel resistance mechanisms as well as subsets of patients who may derive maximal benefit from PI3K pathway inhibitors. Significance: There are multiple ongoing clinical trials targeting the PI3K pathway members in several malignancies. This review summarizes the known mechanisms of resistance to targeting the PI3K pathway. Understanding of resistance mechanisms will help to inform more rational clinical trial design to optimize the clinical impact of targeting the PI3K pathway in cancer. Cancer Discov; 3(12); 1345–54. ©2013 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0063

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA
Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Self-citation
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Self-citation
Translational control in stress and apoptosis
Holčı́k, M., & Sonenberg, N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1618 · Cited by 1,409
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Self-citation
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Self-citation
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,227
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C. H., Koutcher, J. A., Scher, H. I., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,227
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
The emerging roles of forkhead box (Fox) proteins in cancer
Myatt, S. S., & Lam, E. W. ‐. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2223 · Cited by 1,077
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Protein Kinase B Kinases That Mediate Phosphatidylinositol 3,4,5-Trisphosphate-Dependent Activation of Protein Kinase B
Stephens, L., Anderson, K. E., Stokoe, D., Erdjument‐Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F. P., Tempst, P., et al. (1998) · Science · doi:10.1126/science.279.5351.710 · Cited by 1,061
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate
Whitman, M., Downes, C. P., Keeler, M. L., Keller, T. L., & Cantley, L. C. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,018
Self-citation
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Internal ribosome entry sites in eukaryotic mRNA moleculesPreprint
Hellen, C. U. T., & Sarnow, P. (2001) · Genes & Development · doi:10.1101/gad.891101 · Cited by 977
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/bj3440427 · Cited by 926
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaPreprint
Weng, A. P., Millholland, J. M., Yashiro–Ohtani, Y., Arcangeli, M.-L., Lau, A. N., Wai, C., Bianco, C. D., Rodríguez, C. G., Sai, H., Tobias, J. W., et al. (2006) · Genes & Development · doi:10.1101/gad.1450406 · Cited by 863
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P. J., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 861
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2824 · Cited by 853
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 829
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth
Palomero, T., Lim, W. K., Odom, D. T., Sulis, M. L., Real, P. J., Margolin, A. A., Barnes, K., O’Neil, J., Neuberg, D. S., Weng, A. P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606108103 · Cited by 821
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation
Whitman, M., Kaplan, D., Schaffhausen, B., Cantley, L., & Roberts, T. (1985) · Nature · doi:10.1038/315239a0 · Cited by 732
Self-citation
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K. M., Herrmann, R., Lynch, K., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 651
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T. Q., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 645
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 612
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 551
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Self-citation
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A. M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 538
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 505
Self-citation
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Balancing Akt with S6K
Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 485
The Akt kinases: Isoform specificity in metabolism and cancer
Gonzalez, E., & McGraw, T. E. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9335 · Cited by 485
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D. M., Sanchez, V. M., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W. J., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 469
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
Tenbaum, S. P., Ordóñez‐Morán, P., Puig, I., Chicote, I., Arqués, O., Landolfi, S., Fernández, Y., Herance, J. R., Gispert, J. D., Mendizabal, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2772 · Cited by 390
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T. E., Selfors, L. M., Worster, D. T., Iwanicki, M., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 387
Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner
Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 374
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA.
Sonenberg, N., Morgan, M. A., Merrick, W. C., & Shatkin, A. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.10.4843 · Cited by 367
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Jankú, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M. T., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 303
4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications
Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 279
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
Liu, P., Cheng, H.-L. M., Santiago, S., Raeder, M. B., Zhang, F., Isabella, A. J., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 258
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc.
Rosenwald, I. B., Rhoads, D. B., Callanan, L., Isselbacher, K. J., & Schmidt, E. V. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6175 · Cited by 256
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Cortés, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K. A., Pivot, X. B., Verma, S., Albanell, J., Conte, P., Lluch, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 252
PTEN Level in Tumor Suppression: How Much Is Too Little?
Carracedo, A., Alimonti, A., & Pandolfi, P. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2488 · Cited by 250
JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires‐Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 247
An Essential E Box in the Promoter of the Gene Encoding the mRNA Cap-Binding Protein (Eukaryotic Initiation Factor 4E) Is a Target for Activation by c-myc
Jones, R. M., Branda, J. A., Johnston, K. A., Polymenis, M., Gadd, M. A., Rustgi, A. K., Callanan, L., & Schmidt, E. V. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4754 · Cited by 240
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Liu, Q., Xu, C., Kirubakaran, S., Zhang, X., Hur, W., Liu, Y., Kwiatkowski, N. P., Wang, J., Westover, K. D., Gao, P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1702 · Cited by 219
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
Ilić, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 217
Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
Choo, A. Y., & Blenis, J. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7659 · Cited by 213
Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 170
Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway
Guo, S., & Sonenshein, G. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8681-8690.2004 · Cited by 169
A second look at cellular mRNA sequences said to function as internal ribosome entry sites
Kozak, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki958 · Cited by 167
The role of c-myc in regulation of translation initiation
Schmidt, E. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207548 · Cited by 166
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Šmída, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165
High‐resolution genomic and expression analyses of copy number alterations in breast tumors
Haverty, P. M., Fridlyand, J., Li, L., Getz, G. A., Beroukhim, R., Lohr, S., Wu, T. D., Cavet, G., Zhang, Z., & Chant, J. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20558 · Cited by 158
Protein synthesis in eukaryotes: The growing biological relevance of cap-independent translation initiation
López‐Lastra, M., RIVAS, A., & Barría, M. I. (2005) · Biological Research · doi:10.4067/s0716-97602005000200003 · Cited by 158
Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor
Hellyer, N. J., Kim, M.-S., & Koland, J. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102079200 · Cited by 156
EphB/EphrinB Receptors and Wnt Signaling in Colorectal Cancer
Clevers, H. C., & Batlle, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3849 · Cited by 152
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase
Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Manzoli, L., & McCubrey, J. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903136775 · Cited by 123
Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
Chiarini, F., Falà, F., Tazzari, P. L., Ricci, F., Astolfi, A., Pession, A., Pagliaro, P., McCubrey, J. A., & Martelli, A. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4884 · Cited by 119
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
McIntyre, J. B., Wu, J. S.-Y., Craighead, P. S., Phan, T., Köbel, M., Lees‐Miller, S. P., Ghatage, P., Magliocco, A. M., & Doll, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.019 · Cited by 117
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Shuttleworth, S. J., Silva, F. A., Cecil, A., Tomassi, C., Hill, T., Raynaud, F. I., Clarke, P. A., & Workman, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011229 · Cited by 103
Resist or die: FOXO transcription factors determine the cellular response to chemotherapy
Gomes, A., Brosens, J. J., & Lam, E. W. ‐. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6920 · Cited by 94
Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1637 · Cited by 87
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 80
Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia
Mansour, M. R., Duke, V. M., Foroni, L., Patel, B., Allen, C. G., Ancliff, P. J., Gale, R. E., & Linch, D. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1474 · Cited by 79
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response
Shepherd, C., Banerjee, L., Cheung, C. W., Mansour, M. R., Jenkinson, S., Gale, R. E., & Khwaja, A. (2012) · Leukemia · doi:10.1038/leu.2012.285 · Cited by 76
Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma
Suda, T., Hama, T., Kondo, S., Yuza, Y., Yoshikawa, M., Urashima, M., Kato, T., & Moriyama, H. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-416 · Cited by 66
Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase
Mo, J., Ann, E., Yoon, J.-H., Jung, J., Choi, Y., Kim, H.-Y., Ahn, J., Kim, S., Kim, M., Hong, J.-A., et al. (2010) · Journal of Cell Science · doi:10.1242/jcs.073924 · Cited by 63
PI3 kinase inhibitors in the clinic: an update.
Kurtz, J., & Ray-Coquard, I. L. (2012) · PubMed · Cited by 55
IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress
Lewis, S. M., & Holčı́k, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401602 · Cited by 54
687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer
Tenbaum, S. P., Ordóñez‐Morán, P., Puig, I., Chicote, I., Arqués, O., Vivancos, A. P., Baselga, J. M., Tabernero, J. M., Munoz, A., & Pálmer, H. G. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71330-8 · Cited by 50
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Walsh, K. J., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., Smith, J., Beaven, A., Jima, D. D., & Davé, S. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1060 · Cited by 49
Phosphoinositides Are Essential Coactivators for p21-Activated Kinase 1
Strochlic, T. I., Viaud, J., Rennefahrt, U. E. E., Anastassiadis, T., & Peterson, J. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.015 · Cited by 47
Down‐regulation of Notch‐dependent transcription by Akt in vitro
Song, J., Park, S., Kim, M., & Shin, I. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.024 · Cited by 40

Flagged first, then by citations

2 of the 110 references couldn’t be matched to a known paper.

Sorted by citations

PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,762
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,437
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 708
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 602
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 581

See all 148

Authors: Klempner, S. J., Myers, A. P., & Cantley, L. C.
Affiliations: Beth Israel Deaconess Medical Center (US)
Corresponding author: Cantley, Lewis C.
ORCID: Klempner, Samuel J.
Cantley, Lewis C.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2013-12-01
Volume: 3
Issue: 12
Pages: 1345-1354
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-13-0063
PMC: PMC3864542
OpenAlex: W2104167441
Cited by: 148
References: 110
Citations by year: 2026: 3 · 2025: 5 · 2024: 6 · 2023: 2 · 2022: 11 · 2021: 19 · 2020: 12 · 2019: 7 · 2018: 11 · 2017: 18 · 2016: 23 · 2015: 18 · 2014: 12
FWCI: 1.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of General Medical Sciences (GM041890, R01GM041890, R37GM041890)
H2020 European Research Council
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: phosphatidylinositol 3-kinase, PI3K inhibitors, drug resistance mechanisms, compensatory signaling, genomic changes, cancer therapy, targeted therapy, PI3K pathway mutations, clinical trial design
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents, Humans, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Translational Research, Biomedical, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks